Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-A, non-B hepatitis.

E A Fagan, R Williams

    Seminars in Liver Disease
    |November 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Non-A, Non-B hepatitis (NANB) is a major cause of chronic liver disease, likely caused by multiple viruses. Further virologic studies are crucial for understanding and characterizing these agents and transmission routes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Intrahepatic cholestasis of pregnancy.

    Clinics in liver disease·2001
    Same author

    Symptomatic neonatal hepatitis A disease from a virus variant acquired in utero.

    The Pediatric infectious disease journal·1999
    Same author

    Extracorporeal liver perfusion.

    Lancet (London, England)·1999
    Same author

    Immunotherapy in the management of sepsis.

    Postgraduate medical journal·1995
    Same author

    Intrahepatic cholestasis of pregnancy.

    BMJ (Clinical research ed.)·1994
    Same author

    Exclusion in liver by polymerase chain reaction of hepatitis B and C viruses in acute liver failure attributed to sporadic non-A, non-B hepatitis.

    Journal of hepatology·1994
    Same journal

    Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

    Seminars in liver disease·2026
    Same journal

    Neutrophils in Liver Diseases: Functions and Challenging Therapies.

    Seminars in liver disease·2026
    Same journal

    Expert Practical Recommendations for Hepatocellular Carcinoma.

    Seminars in liver disease·2026
    Same journal

    Optimizing Liver Cancer Care Through BCLC Principles.

    Seminars in liver disease·2026
    Same journal

    Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

    Seminars in liver disease·2026
    Same journal

    Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

    Seminars in liver disease·2026
    See all related articles

    Area of Science:

    • Hepatology
    • Virology
    • Infectious Diseases

    Background:

    • Non-A, Non-B hepatitis (NANB) is now the predominant form of post-transfusion hepatitis (PTH).
    • It is a significant cause of chronic liver disease globally, particularly in developed nations.
    • Current knowledge of NANB hepatitis is largely inferential due to the lack of identified causative agents.

    Purpose of the Study:

    • To highlight the emergence and significance of NANB hepatitis.
    • To emphasize the need for further research into the causative agents of NANB hepatitis.
    • To underscore the priority of basic virologic studies for understanding this disease.

    Main Methods:

    • This study is a review and analysis of existing knowledge on NANB hepatitis.
    • It focuses on the clinical and epidemiological aspects of the disease.

    Related Experiment Videos

  • It emphasizes the need for virologic characterization of causative agents.

    • Main Results:

    • NANB hepatitis is the leading cause of PTH.
    • Multiple viral agents are suspected to cause NANB hepatitis, with varying incubation periods and transmission routes.
    • The specific agents responsible for NANB hepatitis remain unisolated and uncharacterized.

    Conclusions:

    • NANB hepatitis represents a significant public health challenge.
    • Isolation and characterization of the causative viral agents are essential for effective diagnosis and treatment.
    • Prioritizing basic virologic research is critical for advancing our understanding and management of NANB hepatitis.